News >

Radium-223 Retreatment Shows Promise in mCRPC

Jason Harris
Published: Wednesday, Nov 22, 2017

Prostate Cancer
A second course of radium-223 (Xofigo) was associated with minimal hematologic toxicity and low radiographic bone progression rates in a phase I/II study of men with metastatic castration-resistant prostate cancer (mCRPC).

Of the 5 patient deaths, 1 occurred during the treatment period. Two deaths were attributed to disease progression, 2 were attributed to AEs not associated with clinical disease progression, and 1 cause of death was unknown.
Sartor O, Heinrich D, Mariados N, et al. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. Ann Oncol. 2017; 28(10):2464-2471.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x